Multiple preclinical and clinical studies demonstrate that specialized nasal and oral sprays can effectively trap, neutralize, or prevent the replication of airborne viruses in the upper respiratory tract.
The retrieved literature consistently supports the claim that various formulations of nasal sprays (including antiviral polymers, immune agonists, and engineered fusion proteins) can successfully neutralize or reduce airborne viral loads and shedding in the upper respiratory tract.